Clincosm LogoSign in Get a demo

Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma

Sponsor
Zhejiang University (Other)
Overall Status
Completed
CT.gov ID
NCT05714722
Collaborator
(none)
60
Enrollment
120
Actual Duration (Months)

Study Details

Study Description

Brief Summary

Background: Colorectal neuroendocrine carcinomas (CRNECs) are highly aggressive tumours with poor prognosis and low incidence. To date, the genomic landscape and molecular pathway alterations have not been elucidated.

Methods: Tissue sections and clinical information were collected as an in-house cohort (2010-2020). Large-scale genomic and genetic panels were applied to identify the genomic and genetic alterations of CRNEC. Through the depiction of the genomic landscape and transcriptome profile, we compared the difference between CRNEC and CR neuroendocrine tumours (CRNETs). Immunohistochemistry (IHC) staining and immunofluorescence (IF) staining were performed to confirm the genetic alterations.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    60 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma
    Actual Study Start Date :
    Jan 1, 2011
    Actual Primary Completion Date :
    Jan 1, 2021
    Actual Study Completion Date :
    Jan 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. overall survival [2010-2020]

    Secondary Outcome Measures

    1. Comprehensive genomic and expression panels (AmoyDx® Master Panel) for dna and rna detection [2020]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • tissues from colorectal neuroendocrine carcinomas
    Exclusion Criteria:
    • no

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Zhejiang University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Weijia Fang, MD, Director, Zhejiang University
    ClinicalTrials.gov Identifier:
    NCT05714722
    Other Study ID Numbers:
    • WFang
    First Posted:
    Feb 6, 2023
    Last Update Posted:
    Feb 6, 2023
    Last Verified:
    Jan 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Carcinoma
    Carcinoma, Neuroendocrine

    Study Results

    No Results Posted as of Feb 6, 2023